SSG
FOLD

Summit Securities Group’s Amicus Therapeutics FOLD Stock Holding History

Summit Securities Group’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-595
Closed -$6K – 728
2024
Q3 		$6K Buy
+595
New +$6.48K ﹤0.01% 418

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Summit Securities Group's FOLD Position: Q4 2024 in Review

Summit Securities Group sold out of Amicus Therapeutics (FOLD) in Q4 2024, closing a stake of 595 shares — an estimated $6K sold.

Summit Securities Group first reported a position in FOLD in Q3 2024 and held it in 1 quarter. The position peaked at $6K in Q3 2024. 290 funds tracked by Wall St. Rank hold FOLD as of Q4 2024.

  • Summit Securities Group reported no remaining Amicus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Summit Securities Group sold 595 Amicus Therapeutics shares in Q4 2024, an estimated $6K.
  • Summit Securities Group first reported a position in Amicus Therapeutics in Q3 2024 and held it in 1 quarter.
  • Summit Securities Group's Amicus Therapeutics position peaked at $6K in Q3 2024.
  • 290 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2024.

Based on Summit Securities Group's 13F filing for Q4 2024, filed 12 Feb 2025.